What's Happening

Stay up to date on conferences, social posts, and what’s new with Healthesystems

Events

Let’s connect at one of our upcoming conferences or speaking engagements
March 18 - Mar 20, 2024

CO WCEC

Healthesystems is attending the Colorado Workers' Compensation Education Conference for stakeholders in Colorado workers' comp.

Broadmoor, CO
March 21 - Mar 22, 2024

California DWC Annual Conference

Healthesystems is attending the California Division of Workers’ Compensation Annual Educational Conference for those who participate in the CA workers’ comp system.

Los Angeles, CA
View all Events

MedMonitor

An up-to-date timeline of FDA approvals that could impact workers' comp
View All MedMonitor Information

Namzaric® (memantine and donepezil hydrochloride) extended release capsules

Approval Date: Dec 2023

Note: First-Time Generic

Indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily

hello world!

Zepbound (tirzepatide) injection

Approval Date: Nov 2023

Note: New Product

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese adults, or overweight adults with at least one weight-related comorbidity

hello world!

Zituvimet (sitagliptin and metformin hydrochloride) tablets

Approval Date: Nov 2023

Note: New Product

Indicated as an adjunct to diet and exercise to improve glycemic control of type 2 diabetes

hello world!

Voquezna (vonoprazan fumarate) tablets

Approval Date: Nov 2023

Note: New Product

Indicated for erosive esophagitis and the relief of heartburn associated with erosive esophagitis

hello world!

Zymfentra (infliximab-dyyb) injection

Approval Date: Oct 2023

Note: New Product

Indicated for the maintenance treatment of moderate to severe ulcerative colitis or moderate to severe Crohn’s disease, following treatment with an infliximab product administered intravenously

hello world!

Omvoh (mirikizumab-mrkz) injection

Approval Date: Oct 2023

Note: New Product

A first-in-class agent indicated for the treatment of moderate to severe ulcerative colitis

hello world!

Wezlana (ustekinumab-auub) injection

Approval Date: Oct 2023

Note: Biosimilar

A biosimilar to Stelara, indicated for the treatment of moderate to severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis

hello world!

Velsipity (estrasimod) tablets

Approval Date: Oct 2023

Note: New Product

Indicated for the treatment of moderate to severe ulcerative colitis

hello world!

Cosentyx® (secukinumab) injection for intravenous use

Approval Date: Oct 2023

Note: New Dosage or Formulation

Indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and other autoimmune conditions, this drug is now available in an intravenous formulation

hello world!

Bimzelx® (bimekizumab-bkzx) injection for subcutaneous use

Approval Date: Oct 2023

Note: New Product

Indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

hello world!
1 2 3 12

Social Hub

Check out our latest posts and activity
View All Social Media
    lockenvelopephone-handsetmagnifiermenucross-circle